Stay informed about the development of COVID-19 products
Biotechgate is a fully virtual source of information about the life science industry and a great solution for those seeking to stay up to date when all real-life events are cancelled or postponed.
Our database is updated daily which is particularly important now, given the pace of work on the development of COVID-19 vaccines, tests, and treatments.
Below we summarized the data about COVID-19 biotech products.
To see details, please, apply for free trial access to Biotechgate.
COVID-19 vaccines
Technology platform
| Label | Amount | |
|---|---|---|
| Protein Subunit | 36% | |
| Non-Replicating Viral Vector | 14% | |
| RNA | 13% | |
| Replicating Viral Vector | 11% | |
| DNA | 9% | |
| VLP | 7% | |
| Inactivated | 7% | |
| Live Attenuated Virus | 2% | |
| Unknown | 1% |
Current stage of clinical evaluation
| Label | Count | |
|---|---|---|
| Pre-Clinical | 126 | |
| Phase 1 | 5 | |
| Phase 1/2' | 5 | |
| Phase 2 | 2 | |
| Phase 2b/3' | 1 |
Type of company
| Label | Amount | |
|---|---|---|
| Public companies | 22% | |
| Private Companies | 37% | |
| Institutions | 41% |
COVID-19 treatments
Technology platform
| Label | Amount | |
|---|---|---|
| Antibodies | 32% | |
| Antiviral | 12% | |
| Cell-based Therapy | 7% | |
| RNA-based treatments | 3% | |
| Others | 46% |
Current stage of clinical evaluation
COVID-19 tests
Technology
| Label | Amount | |
|---|---|---|
| PCR | 72% | |
| Serological | 24% | |
| Cell-based Therapy | 7% | |
| isothermal amplification | 2% | |
| Sequencing | 1% | |
| Antigen | 1% |
Number of approved tests by region
To see more details request a free trial to Biotechgate.
Explore our database of over 50,000 companies